{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:44:33Z","timestamp":1789411473348,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104476"],"award-info":[{"award-number":["82104476"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40264-023-01334-z","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T10:02:30Z","timestamp":1688724150000},"page":"881-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Disproportionality Analysis of Abemaciclib in\u00a0the\u00a0FDA Adverse Event Reporting System: A\u00a0Real-World Post-Marketing Pharmacovigilance Assessment"],"prefix":"10.1007","volume":"46","author":[{"given":"Yamin","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4779-3875","authenticated-orcid":false,"given":"Qilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"6","key":"1334_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"1334_CR2","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","volume":"34","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34(25):3069\u2013103.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1334_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/cancers13020332","volume":"13","author":"M Roberto","year":"2021","unstructured":"Roberto M, Astone A, Botticelli A, Carbognin L, Cassano A, D\u2019Auria G, et al. CDK4\/6 inhibitor treatments in patients with hormone receptor positive, Her2 negative advanced breast cancer: potential molecular mechanisms, clinical implications and future perspectives. Cancers. 2021;13(2):332.","journal-title":"Cancers"},{"issue":"10226","key":"1334_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817\u201327.","journal-title":"Lancet"},{"issue":"25","key":"1334_CR5","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1334_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116\u201324.","journal-title":"JAMA Oncol"},{"key":"1334_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.","journal-title":"NPJ Breast Cancer."},{"issue":"32","key":"1334_CR8","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346.","journal-title":"J Clin Oncol"},{"key":"1334_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijbiomac.2022.07.156","volume":"218","author":"M Yousuf","year":"2022","unstructured":"Yousuf M, Alam M, Shamsi A, Khan P, Hasan GM, Rizwanul Haque QM, et al. Structure-guided design and development of cyclin-dependent kinase 4\/6 inhibitors: a review on therapeutic implications. Int J Biol Macromol. 2022;218:394\u2013408.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"1334_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317\u201331.","journal-title":"Drugs"},{"key":"1334_CR11","unstructured":"National Comprehensive Cancer Network. NCCN guidelines in breast cancer, version 4. 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 2 Nov."},{"key":"1334_CR12","unstructured":"Chinese Society of Clinical Oncology. CSCO guidelines in diagnosis and treatment of breast cancer. 2022. http:\/\/www.csco.org.cn\/cn\/index.aspx. Accessed 6 Sep."},{"issue":"7","key":"1334_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","volume":"6","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6(7):740\u201353.","journal-title":"Cancer Discov"},{"key":"1334_CR14","doi-asserted-by":"crossref","unstructured":"Yan MM, Wu SS, Qi YP, Li ZR, Zhang Q, Zhao H, et al. Association between cyclin-dependent kinase 4\/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data. Expert Opin Drug Saf. 2022;21(2):277\u201383.","DOI":"10.1080\/14740338.2021.1981856"},{"issue":"8","key":"1334_CR15","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/cancers13081758","volume":"13","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Thromboembolic events with cyclin-dependent kinase 4\/6 inhibitors in the FDA Adverse Event Reporting System. Cancers. 2021;13(8):1758.","journal-title":"Cancers"},{"issue":"1","key":"1334_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","volume":"186","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA Adverse Event Reporting System: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186(1):219\u201327.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1334_CR17","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, Masuda N, Sohn JH, Andre VAM, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26(1):e53-65.","journal-title":"Oncologist"},{"key":"1334_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Liu Y, Wu P, He X, Zhang Q. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA Adverse Event Reporting System. Front Pharmacol. 2022;13: 862508.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1334_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","volume":"21","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Dai B, Zhang Q. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2022;21(4):563\u201372.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1334_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1334_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pds.771","volume":"12","author":"AL Gould","year":"2003","unstructured":"Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003;12(7):559\u201374.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1334_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"JS Almenoff","year":"2007","unstructured":"Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1334_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","volume":"20","author":"BM Bonora","year":"2021","unstructured":"Bonora BM, Raschi E, Avogaro A, Fadini GP. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration Adverse Event Reporting System. Cardiovasc Diabetol. 2021;20(1):39.","journal-title":"Cardiovasc Diabetol"},{"key":"1334_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.996179","volume":"10","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA Adverse Event Reporting System. Front Public Health. 2022;10: 996179.","journal-title":"Front Public Health"},{"issue":"1","key":"1334_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"1334_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti M, Antonazzo IC, Diemberger I, De Ponti F, Raschi E. Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA Adverse Event Reporting System. Eur J Prev Cardiol. 2021;28(9):983\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"1334_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","volume":"35","author":"VR Cornelius","year":"2012","unstructured":"Cornelius VR, Sauzet O, Evans SJ. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf. 2012;35(7):599\u2013610.","journal-title":"Drug Saf"},{"issue":"10","key":"1334_CR28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36(10):995\u20131006.","journal-title":"Drug Saf"},{"key":"1334_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","volume":"1","author":"M Nakamura","year":"2015","unstructured":"Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, et al. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci. 2015;1:34.","journal-title":"J Pharm Health Care Sci."},{"issue":"4","key":"1334_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425\u201339.","journal-title":"Lancet Oncol"},{"issue":"18","key":"1334_CR31","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast Ccncer. N Engl J Med. 2016;375(18):1738\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"1334_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-017-4518-8","volume":"168","author":"J O'Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;168(1):127\u201334.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1334_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","volume":"18","author":"S Thibault","year":"2019","unstructured":"Thibault S, Hu W, Hirakawa B, Kalabat D, Franks T, Sung T, et al. Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary pharmacology. Mol Cancer Ther. 2019;18(2):257\u201366.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1334_CR34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541\u20137.","journal-title":"Ann Oncol"},{"issue":"24","key":"1334_CR35","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465\u201372.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1334_CR36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514\u201324.","journal-title":"N Engl J Med"},{"issue":"20","key":"1334_CR37","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336.","journal-title":"N Engl J Med"},{"issue":"3","key":"1334_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719\u201329.","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"1334_CR39","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/onc.2015.407","volume":"35","author":"AS Tigan","year":"2016","unstructured":"Tigan AS, Bellutti F, Kollmann K, Tebb G, Sexl V. CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene. 2016;35(24):3083\u201391.","journal-title":"Oncogene"},{"key":"1334_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"SA Im","year":"2019","unstructured":"Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol. 2019;5:1\u201319.","journal-title":"J Glob Oncol."},{"key":"1334_CR41","doi-asserted-by":"publisher","first-page":"175883592096392","DOI":"10.1177\/1758835920963925","volume":"12","author":"QY Zhang","year":"2020","unstructured":"Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:1758835920963925.","journal-title":"Ther Adv Med Oncol."},{"key":"1334_CR42","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;10:1758835918793326.","journal-title":"Ther Adv Med Oncol."},{"issue":"5","key":"1334_CR43","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/hep.28720","volume":"65","author":"R Vuppalanchi","year":"2017","unstructured":"Vuppalanchi R, Saxena R, Storniolo AMV, Chalasani N. Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib. Hepatology. 2017;65(5):1762\u20134.","journal-title":"Hepatology"},{"issue":"5","key":"1334_CR44","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/cpt.1296","volume":"105","author":"JC Chappell","year":"2019","unstructured":"Chappell JC, Turner PK, Pak YA, Bacon J, Chiang AY, Royalty J, et al. Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. Clin Pharmacol Ther. 2019;105(5):1187\u201395.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1334_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-020-05783-3","volume":"183","author":"KZ Thein","year":"2020","unstructured":"Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2020;183(2):479\u201387.","journal-title":"Breast Cancer Res Treat"},{"issue":"34","key":"1334_CR46","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"J Clin Oncol"},{"key":"1334_CR47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.thromres.2021.11.009","volume":"208","author":"E Bolzacchini","year":"2021","unstructured":"Bolzacchini E, Pomero F, Fazio M, Civitelli C, Fabro G, Pellegrino D, et al. Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4\/6 inhibitors: a systematic review and meta-analysis. Thromb Res. 2021;208:190\u20137.","journal-title":"Thromb Res"},{"key":"1334_CR48","unstructured":"US Food and Drug Administration. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer. Accessed 10 Aug 2022."},{"key":"1334_CR49","unstructured":"UK Medicines and Healthcare products Regulatory Agency. Available from: https:\/\/www.gov.uk\/drug-safety-update\/cdk4-slash-6-inhibitors-abemaciclibv-palbociclibv-ribociclibv-reports-of-interstitial-lung-disease-and-pneumonitis-including-severe-cases. Accessed 10 Aug 2022."},{"key":"1334_CR50","unstructured":"European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/verzenios-epar-risk-management-plan-summary_en.pdf. Accessed 10 Aug 2022."},{"issue":"1","key":"1334_CR51","volume":"5","author":"H Nawa","year":"2022","unstructured":"Nawa H, Niimura T, Yagi K, Goda M, Zamami Y, Ishizawa K. Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments. Cancer Rep (Hoboken). 2022;5(1): e1402.","journal-title":"Cancer Rep (Hoboken)."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01334-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01334-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01334-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T13:12:13Z","timestamp":1692623533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01334-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1334"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01334-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"20 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by grants from the National Natural Science Foundation of China (no. 82104476).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yamin Shu, Lei Wang, Yiling Ding, and Qilin Zhang have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This study was approved (no. 20220185) by the Institutional Ethics Board of the Union Hospital of Tongji Medical College of Huazhong University of Science and Technology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The database used in this study is publicly available on the website of\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"QZ and YS contributed to the conception of the study and the study design, took responsibility for the collection, integrity, and analysis of the data, and drafted the manuscript. All authors participated in revisions of the manuscript and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}